Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016
Published Jul 30, 2016
65 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016, provides in depth analysis on Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted pipeline therapeutics.

The report provides comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indicat

  
Source:
Document ID
GMDHC0431TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Overview71
Therapeutics Development83
  Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Stage of Development81
  Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Therapy Area91
  Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Indication101
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Companies132
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Companies Involved in Therapeutics Development216
  Alteogen Inc.211
  Clearside BioMedical, Inc.221
  CSL Limited231
  Eli Lilly and Company241
  Formycon AG251
  Regeneron Pharmaceuticals, Inc.261
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Drug Profiles2724
  (aflibercept + nesvacumab) Drug Profile271
  (aflibercept + rinucumab) Drug Profile281
  (aflibercept + triamcinolone acetonide) Drug Profile293
  2H-10 Drug Profile321
  aflibercept Drug Profile3310
  aflibercept biosimilar Drug Profile431
  aflibercept biosimilar Drug Profile441
  CSL-346 Drug Profile451
  Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology Drug Profile461
  ziv-aflibercept Drug Profile474
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Dormant Projects511
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Discontinued Products521
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Featured News &Press Releases5311
  Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance531
  May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection541
  Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion541
  Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven551
  Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept)561
  Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration561
  Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization571
  Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication571
  Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema581
  Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition591
  Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan591
  Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance601
  May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice602
  Apr 01, 2015: New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection621
  Mar 25, 2015: EYLEA (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema631
Appendix642
  Methodology641
  Coverage641
  Secondary Research641
  Primary Research641
  Expert Panel Validation641
  Contact Us641
  Disclaimer651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vascular-Endothelial-Growth-Factor-B-VEGF-Related-Factor-or-VEGFB-Pipeline-Review-H2-2016-2088-16329>
  
APA:
Global Markets Direct - Market Research. (2016). Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vascular-Endothelial-Growth-Factor-B-VEGF-Related-Factor-or-VEGFB-Pipeline-Review-H2-2016-2088-16329>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.